4/22/2005 Anaheim, CA Charlene Laino WebMD Health (my.webmd.com) New studies presented at a major cancer meeting reinforce the old adage that you are what you eat (and drink). One study shows that green tea may stave off prostate cancer. Another study suggests that eating a lot of hot dogs, sausage, and other processed meats may raise the risk of pancreatic cancerrisk of pancreatic cancer. Loading up on red meat also seems to increase the chance of developing pancreatic cancer, one of the most deadly of tumors, says study researcher Ute Nothlings, DrPH, MSE. "The findings suggest that eating less processed meat and less red meat might help prevent pancreatic cancer," she tells WebMD. Nothlings is a researcher at the Cancer Research Center at the University of Hawaii in Honolulu. Red meat has also been linked to an increase in colon cancer.linked to an increase in colon cancer. Diving Into the Meat of the Matter For the study, the researchers examined the relationship between diet and pancreatic cancer among nearly 200,000 men and women. When they first entered the study in the mid-1990s, all the participants filled out a detailed questionnaire that asked what foods they had eaten in the past year, how frequently they had eaten them, and how much they had eaten. By an average of seven years later, 482 of the men and women had developed pancreatic cancer. Those who ate more than 1.5 ounces of processed meat a day were about two-thirds more likely to have pancreatic [...]

4/22/2005 Beverly, MA Roger W. Sachs, D.M.D Damvers Herald on Townline.com The majority of oral carcinoma is preventable and the earlier the diagnosis, the better the cure. Oral cancers that are caught early have probably well over a 90-95 percent cure ratio, whereas those cancers that have gone on for a year or more, have cure rates that are greatly reduced. Oral cancer can be seen in any part of the mouth. The most common areas are the sides of the tongue and back of the mouth, at the point where the lower ridge meets the back of the mouth. Other areas include the lips and cheeks and under the tongue. Oral cancer can certainly start at any age, but the average s between the ages of 50-75. In my over twenty-five years of practice, with the exception of three cases, all of the cancer cases I have treated have been caused by smoking or alcohol abuse. The more recent phenomena of chewing tobacco may also cause oral carcinoma, but at present there is no conclusive proof. In oral surgery there is a saying that states "if you smoke long enough, you will get cancer." The medical and dental community would practically go out of business if smoking completely ceased. There would be hardly any oral cancer, lung cancer, emphysema and heart disease would be greatly reduced. In addition to smoking and alcohol abuse, other causes of oral cancer include spreading from other cancer sites, called metastasis, or cancers from [...]

4/22/2005 Israel Medical News Today (www.medicalnewstoday.com) In a recent study published in Molecular Cancer Therapeutics, researchers at the Weizmann Institute of Science paired the active ingredient of a garden remedy with advanced bio-technology to deliver a powerful punch against cancer. The cancer killing effectiveness lies in their technique of arming a cancer-targeting antibody with the destructive potential of the dietary molecule otherwise known as "allicin." Allicin is the product of an interaction between an enzyme, alliinase, and the small chemical alliin, which occurs naturally in plants such as garlic and onion as a defense mechanism against soil fungi, bacteria and parasites. Allicin molecules can easily penetrate biological membranes and kill cells, but their potency is short-lived hence the difficulty in finding a system to deliver them to a specific site. "The medicinal value of garlic is no longer an ancient Chinese secret," says the Institute's Prof. David Mirelman. "Years of scientific research led to the identification and understanding of allicin's mode of activity and we are currently studying ways to target and deliver its toxic punch." The team, including Mirelman, Prof. Meir Wilchek, Drs. Fabian Arditti, Talia Miron and Aharon Rabinkov of the Biological Chemistry Department, and Prof. Yair Reisner of the Immunology Department, together with Prof. Berrebi of Rehovot's Kaplan Hospital, adopted an approach that fastens the enzyme alliinase onto a specific antibody already in clinical use, Rituximabâ, designed to target and lock on to the surface of certain types of cancer cells such as lymphoma. When administered alone, [...]

4/20/2005 Ann Arbor, MI University of Michigan News Service The Detroit Oral Cancer Prevention Project has launched a citywide campaign to lower the oral cancer death rate in Detroit. “Our best hope for decreasing the rate of oral cancer is to get Detroiters in for a screening,” said project director Dr. Amid Ismail, from the University of Michigan School of Dentistry. “If caught early, oral cancer has a 90 percent cure rate.” The effects of later-stage oral cancer treatments, by contrast, can be devastating. Some patients require full or partial removal of the tongue, teeth, gums or oral tissues. Detroit has one of the highest rates of oral cancer in the nation. According to a recent study, 46 percent of all deaths from oral cancer in Michigan occur in the Detroit area. In African-American men, Detroit reported an oral cancer rate of 31 cases per 100,000 people, which was the highest rate reported among all states. The Detroit area, with one of the highest incidence and mortality rates of oral cancer in the state, had only 35 percent of its oral cancer cases detected at an early (localized) stage. Among the risk factors of oral cancer are tobacco use, moderate or heavy alcohol use, a diet low in fruits and vegetables, lack of access to early screening and dental care, and poor oral hygiene. The Detroit Oral Cancer Prevention Program seeks to reduce the oral cancer death rate in Detroit by half in the next five years. The campaign, titled [...]

4/20/2005 Anaheim, CA www.cancerpage.com Using microarray analysis, cancer researchers have identified an 11-gene signature that is strongly associated with a poor response to treatment, increased risk of metastatic spread, and shorten survival in patients with a variety of primary tumor types. The data "seem to indicate the presence of a conserved BMI-1 oncogene-driven pathway similarly engaged in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as high probability of treatment failure," the researchers explain in an abstract of the 96th annual meeting of the American Association for Cancer Research. Early identification of cancer patients with the 11-gene so-called "death from cancer signature" will allow clinicians and patients to consider therapeutic strategies beyond the conventional at the time of diagnosis, said Dr. Gennadi V. Glinksy from the Sidney Kimmel Cancer Center in San Diego. According to the team, 93% of human and 87% of mouse tissues analyzed manifest negative (non-stem cell-like) expression profiles of the 11-gene signature. They evaluated the prognostic power of the 11-gene signature in several independent therapy outcome data sets of clinical samples obtained from 1566 cancer patients diagnosed with 10 different types of cancer: prostate, breast, lung, ovarian, bladder, lymphoma, mesothelioma, medulloblastoma, glioma, and acute myeloid leukemia. Kaplan-Meier analysis showed that a stem cell-like expression profile of the 11-gene signature in primary tumors was a "consistent powerful predictor" of a short time to disease recurrence, [...]

4/19/2005 Anaheim, CA press release EurekAlert! To most, the mere mention of the word "virus" stirs up memories of pain, fever and varying levels of suffering. But in recent years, scientists have been trying to turn these long-time medical foes into allies in the fight against cancer. Through genetic engineering, viruses are being re-programmed to take advantage of their natural abilities to infiltrate, commandeer, replicate and destroy, but only in tumor cells and not surrounding healthy tissue. Several of these "oncolytic" (cancer-killing) viruses are in varying stages of development, including modifications of the virus that causes measles and another, the herpes simplex virus, responsible for those lip blisters known as cold sores. In studies presented this week at the 96th meeting of the American Association for Cancer Research (AACR), researchers describe their latest studies with their engineered versions of these viruses. Cold Sore Virus Modified to Halt Growth and Spread of a Variety of Tumors: Abstract 5292 A modified herpes simplex virus, built with a potent immune stimulant to thwart the spread of cancer cells, is being tested in patients with a variety of tumor types, including melanoma, breast, head and neck, and colorectal cancer. In early clinical studies, the engineered virus -- developed by Biovex Ltd. under the trade name OncoVEX -- showed promise of causing necrosis (death) of tumors cells in most patients. "Tumor necrosis was evidenced clinically and/or by histology in biopsies taken about two weeks after the final dose in a number of patients," said Jennifer [...]

4/19/2005 Ann Arbor, MI press release University of Michigan Health Service A compound derived from cottonseed oil could help improve the effectiveness of chemotherapy at treating head and neck cancer, researchers at the University of Michigan Comprehensive Cancer Center have found. The findings, which will be presented Tuesday, April 19, at the American Association for Cancer Research annual meeting, could lead to a treatment that provides an effective option to surgically removing the cancer, helping patients preserve vital organs involved in speech and swallowing. While new treatments in head and neck cancer have allowed some patients to undergo chemotherapy and radiation therapy instead of surgery, this form of cancer is often resistant to chemotherapy. When the cancer does not respond to these powerful drugs, patients must resort to surgery. “Patients really benefit long-term by avoiding surgery because the side effects of surgery for head and neck cancer can be particularly difficult for patients – it’s how you talk, and how you swallow and how you breathe,” says Carol Bradford, M.D., professor of otolaryngology at the U-M Medical School and co-director of the Head and Neck Oncology Program at the U-M Comprehensive Cancer Center. The compound, (-)-gossypol, works to regulate a protein called Bcl-xL that’s overexpressed in cancer cells and makes these cells survive when they shouldn’t. Shaomeng Wang, Ph.D., co-director of the Molecular Therapeutics Program at the U-M Comprehensive Cancer Center, discovered (-)-gossypol, a compound derived from a component of Chinese medicine. Gossypol comes from cottonseed oil and was once [...]

4/19/2005 Ann Arbor, MI Philip Svabik The Michigan Daily People diagnosed with brain cancer may soon have access to more effective therapy options, thanks to an advanced MRI scan that can chart the success of a particular treatment early on in the course of therapy, a new University of Michigan study suggests. Currently, once a patient is diagnosed with brain cancer, they enter into therapeutic treatment of either radiation therapy or chemotherapy for about six to seven weeks. Patients then must wait six to twelve weeks after the treatment period has ended to return for a follow up image that will prove if the treatment was effective or not. “If you didn’t respond to the treatment, then you have gone through almost three months of ineffective intervention,” said Brian Ross, a professor of radiology and biological chemistry at the University and one of the study’s 14 authors. “And now you are faced with the gloomy task of essentially deciding what you are going to select next in consultation with your physician,” he added. However, Ross and his colleagues have found that by using a special MRI scan, called an MRI diffusion map, they can evaluate the effectiveness of the treatment at a mere three weeks into it — roughly 10 weeks earlier than if standard MRI imaging procedures were used. Diffusion MRI works by measuring the flow of the water surrounding the brain through the tumor, which helps measure the density of the tumor. The researchers found that if after [...]

4/19/2005 Cori Vanchieri Journal of the National Cancer Institute, Vol. 97, No. 8, 552-553, April 20, 2005 Several cyclooxygenase 2 (COX-2) inhibitors have taken a beating from recent evidence that they can cause deaths from heart attack and stroke, but some cancer researchers say that the drugs are too promising as possible chemoprevention agents to abandon them completely. Rofecoxib (Vioxx) was withdrawn from the market in September when a colon cancer chemoprevention trial revealed an increased risk of heart attacks and strokes among long-term users (see News, Vol. 96, No. 23, p. 1734, "Vioxx Withdrawal Alarms Cancer Prevention Researchers"). Soon after, valdecoxib (Bextra) was shown to increase heart attacks in people who recently had coronary artery bypass surgery. Bad news for celecoxib (Celebrex), the COX-2 inhibitor used most frequently in prevention trials, came in December: It also increased the risk of heart attacks in a cancer prevention trial. Drug administration was stopped on dozens of cancer prevention trials, other studies were halted, and a U.S. Food and Drug Administration hearing was planned. Two FDA panels—the Arthritis Drug Advisory Committee and the Drug Safety and Risk Management Advisory Committee—met jointly in mid-February. Overall, they viewed the cardiovascular risk as a class effect among the group of COX-2 inhibitors. But they voted to keep on the market the two drugs that are still being sold—celecoxib and valdecoxib—with new black box warnings and limits on direct-to-consumer marketing. They also voted narrowly to leave the door open for Merck to return rofecoxib to the [...]

4/19/2005 Scotland, United Kingdom Scotland Today Cancer specialists say not enough people know about mouth cancer, even though the west of Scotland has the highest incidence of the disease in the UK. TV adverts will be back on our screens tonight to remind people of the tell-tale signs. Every year more than 500 Scots find out that they have mouth cancer. The west of Scotland has a much higher incidence rate than anywhere else in the UK and unfortunately the figures are rising. That is why a television advert which is designed to raise awareness of the disease and it's symptoms is being relaunched this week. Jim Baillie says that watching that very ad last November may well have saved his life. He said: "It related to me, the little tongue, I had the symptoms and I thought "I don't like the looks of this". The chaps that did that ad, I mean I owe them everything." Consultant surgeon John Devine said: "If a mouth cancer is picked up at an early stage the treatment is actually very straightforward and very quickly the patient can get back to a near normal quality of life." He added: "The main symptoms are an ulcer that hasn't healed up after three to four weeks but there are some other signs and symptoms like white patches in the mouth, red patches, sometimes if teeth become loose for no explained reason and the message from us is if in any doubt at all get along [...]